About Us

Brigitte Boldyreff,  Dr.rer.nat.habil, B.Sc ., Has more than 20 years' experience in biotechnology commercialization. She is founder of Kinase Logistics ApS, a solo company which now currently serves as European Agent for the Japanese company Carna Biosciences Inc. She holds a PhD degree in Molecular Biology from the University of Lübeck, Germany and a BS degree in Human Nutrition and Health from the University College Haderslev, Denmark. She had been working as Executive Director at Kinase Logistics ApS,  as CSO at KinaseDetect ApS and had been Associate Professor at the Institute of Biochemistry and Molecular Biology, University of Southern Denmark. She has a strong interest in receptor and signal transduction mechanisms as these related to mechanisms of action and efficacy, especially the physiological role of protein kinases and their involvement in diseases, as well as impact of nutrition on health. In addition, she has contributed >60 peer reviewed publications in numerous areas including oncology, vascular disease, and bone diseases, among others. 

Adel A. Mikhail, Ph.D., is the founder and CEO of Phylogeny Inc., a company that specializes in tissue analyses and molecular pathology.   Most recently, Dr. Mikhail has merged his company with two other organizations to form Discovery Life Sciences (Phylogeny, Conversant Bio, and Folio Bio).  Dr. Mikhail has more than 25 years in bio-corporate development, investment, and biotechnology applications to new and repurposed drugs and drug development. 

Kenneth C. Williams, Ph.D., is Full Professor in the Department of Molecular Biology at Boston College.  Dr. Williams' work has centered on inflammation and normal and diseased states. This work includes, a) studies to define subpopulations of macrophages in the CNS and their precursors in blood and bone marrow, b) the role of the cellular immune system especially CD8 T cells controlling monocyte/macrophage activation and CNS pathogenesis, and c) developing drugs that target HIV and SIV infected/activated macrophages resulting in cell death or deactivation. In addition, we are exploring an exciting field of emergent populations of monocytes and dendritic cells that are expanded with disease. This work uses a monkey model of rapid, consistent AIDS and neuroAIDS, CD8 T lymphocyte depletion, MR spectroscopy, monocyte/macrophage biology and immunology. Dr. Williams has more than 18 years of experience in the field of inflammation and disease.

George Q. Mills, M.D., M.B.A.  has held several senior roles at the FDA, including as a Division Director in the Center for Drugs (CDER), Branch Chief and designated Acting Deputy Division Director of the Biologics Oncology Division at the Center for Biologics Evaluation and Research (CBER). In these roles, he provided expertise in medical diagnostic imaging and therapeutic radiopharmaceutical oncologic biologics and drugs. He also served as the CBER/CDER expert in conjunction with the review of radiographic imaging submissions in support of multiple licensure submissions. Dr. Mills also served as Vice President of Medical Imaging for Perceptive Informatics, a PAREXEL Company. Dr. Mills has spoken at numerous industry conferences and has published articles in scientific journals and industry publications on imaging and regulatory topics, including the FDA Critical Path Initiative. Dr. Mills has been certified by the American Board of Nuclear Medicine and the American Board of Pathology, Anatomic and Clinical Pathology. Dr. Mills holds a M.D. Degree from Creighton University in Omaha, Nebraska, a M.B.A. degree from Pepperdine University, and a B.A. degree from the University of Nebraska.

Olaf-Georg Issinger, Dr. rer. nat. habil., is Professor emeritus at the Department for Biochemistry and Molecular Biology at the University of Southern Denmark – Odense, DK. Dr. Issinger is founder of KinaseDetect ApS, a privately held company involved in production and sale of protein kinases, substrates and antibodies for pharmaceutical industries. Dr. Issinger’s interest in protein kinase research began as a postdoctoral fellow at the Univ. of Calif. Davis. He continued his career as Assistant professor at the Univ. of Stuttgart and Associate professor at the Medical Faculty of Saarland University – Homburg/Saar, Germany. He worked as a guest scientist at the National Cancer Center in Tokyo (1986/87) and at the St. Vincent’s Institute, Melbourne, Australia (2009). He received several special awards and serves as reviewer on various boards and international Journals. Dr. Issinger received his M.S. from the Free University in Berlin and his Ph.D. from Freiburg University, Germany. Dr. Issinger has authored over 180 scientific articles in the fields of protein kinases, signal transduction and cancer.   

Gerald M. Haase, MD, is Clinical Professor of Surgery at the University of Colorado, School of Medicine and principal of Rocky Mountain Medical Research. He co-founded of a nutritional science research and development entity that was acquired by a public company, New Age Corporation, of which he became Chief Medical Officer. He was the co-founder of CURE, a non-profit foundation assisting China in management of cancer in children. Dr. Haase has been actively involved in medical research and clinical trials for 35 years including the design of central venous access devices, applications for intra-operative radiation therapy in pediatric solid tumors, technical surgical innovations in adult and childhood cancer, and development of novel strategies for antioxidant micronutrient therapy for war fighter protection, adverse clinical conditions, against hazardous exposures.    Dr. Haase also served as chairman of the Board of Scientific Counselors of the Cancer Treatment Research Foundation and as a senior member of the Commission on Cancer of the American College of Surgeons. He was appointed to the Board of Trustees of the National Childhood Cancer Foundation and served on its Medical and Scientific Advisory Board. He has published/ presented more than 200 scientific papers, is the inventor/co-inventor of ten issued U.S. patents for micronutrient and phytonutrient therapy with five pending patents and been the recipient of clinical research grants and contracts funded at a several million-dollar cumulative level.   Dr. Haase participated with the International Office of the National Cancer Institute and has been an examiner in pediatric surgery for the American Board of Surgery. He is a member of more than 25 professional societies including the American Association for Cancer Research, International College of Surgeons, American Academy of Pediatrics, New York Academy of Sciences, American College of Physician Executives, and is a charter member of the International Society of Pediatric Surgical Oncology. In addition, he served on the Board of Directors of the Pacific Association of Pediatric Surgeons.  Dr. Haase received his undergraduate degree from the Johns Hopkins University and M.D. degree from Tufts University School of Medicine with graduate honors in research. His surgical training was at the University of Colorado, Health Sciences Center and he specialized in pediatric surgery and oncology at Children’s Hospital Medical Center, Boston, and Nationwide Children’s Hospital, Columbus, Ohio. 

· Develop relationships that make a positive difference patients’ lives.

· Deliver life-improving value to patients. 

· Uphold the highest research and clinical study standards always.

· Work together, across boundaries, to meet the needs of patients.

· Respect for People - value our people, encourage development and reward performance.

· We are good citizens and stewards in the global communities in which we work.

· Exhibit a strong will to win in the marketplace and in every aspect of our business. 

· We are responsible for our own success and the delivery of life-improving products.

Physis is proceeding aggressively to become a leader in new, specialty, and off-patent medicines. Physis is formed as a global operation in support of a strategy and vision where Physis delivers an enduring health impact across its ethical product line of medicines. Physis intends to act as a trusted and respected associate in the healthcare sphere. Physis seeks to provide reasonable cost healthcare in areas of health crisis and to all economic environs, with a goal of making healthcare available to all in need.